{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000670","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.509288+00:00","generated_at":"2026-06-16T04:20:56.634553+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEXX Q1 revenue $900M (+8% reported, +10% organic); EPS $2.55; raises 2023 guidance","bullets":["Q1 revenue $900M, up 8% reported, 10% organic; CAG Diagnostics recurring revenue up 9% reported, 12% organic.","EPS $2.55, up 12% reported, 18% comparable; includes $0.06 tax benefit and $0.11 negative FX impact.","Raises FY2023 revenue guidance to $3,615M-$3,700M (7.5%-10%) and EPS guidance to $9.33-$9.75 (16%-22% reported).","Record Q1 global premium instrument placements; U.S. CAG Diagnostics organic recurring revenue grew 14%, 1,350 bps premium to clinic visits.","Operating margin 31.1%, up 150 bps reported, 210 bps comparable; gross margin 60.3%, up 70 bps reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000670","json":"https://secwatch.observer/filing/0001157523-23-000670.json","markdown":"https://secwatch.observer/filing/0001157523-23-000670.md","text":"https://secwatch.observer/filing/0001157523-23-000670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000115752323000670/0001157523-23-000670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000115752323000670/a53391037.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:20:56.634553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"02951fadb6baeec8b1630f52300f6fdd9b2ecece","claim":"IDEXX LABORATORIES INC /DE reported quarter ended March 31, 2023 results: revenue $900 million, EPS $2.55.","evidence_excerpt":"First Quarter Results The Company reports revenues of $900 million for the first quarter of 2023, an increase of 8% reported and 10% organic, driven by Companion Animal Group (\"CAG\") Diagnostics recurring revenue growth of 9% reported and 12% organic. First quarter results were supported by continued solid demand for veterinary services and benefits from strong IDEXX execution, reflected in 14% reported and organic growth in U.S. CAG Diagnostics recurring revenues and double-digit organic gains across IDEXX's major testing modalities. IDEXX innovation and commercial engagement drove record first quarter global premium instrument placements, supporting 11% annual growth in IDEXX's global premium instrument installed base. Veterinary software, services and diagnostic imaging systems revenue grew 13% as reported and 14% organically, reflecting high growth in recurring revenues and continued strong quarterly placements of cloud-based software solutions. Overall first quarter revenue gains","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874716/000115752323000670/0001157523-23-000670-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Revenue","value":"$900 million"},{"label":"EPS","value":"$2.55"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2eddd3851a18d49bea4fcdcda2b883206218575d","claim":"IDEXX LABORATORIES INC /DE reported full year 2023 results: revenue $3,615 million - $3,700 million, EPS $9.33 - $9.75. Guidance raised.","evidence_excerpt":"Increases 2023 revenue guidance to $3,615 million - $3,700 million, reflecting 7.5% - 10% growth as reported and organically Updates 2023 EPS outlook to $9.33 - $9.75, a year-over-year increase of 16% - 22% as reported and 20% - 26% on a comparable basis, including ~12% combined growth benefit from a customer contract resolution payment in Q1 2023 and lapping of discrete 2022 R&D investments","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874716/000115752323000670/0001157523-23-000670-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$3,615 million - $3,700 million"},{"label":"EPS","value":"$9.33 - $9.75"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}